Opinion & analysis

Sunscreen Test Lab Used Fewer Subjects Than Reported, US Prosecutors Allege

The owner of AMA Labs, which provides testing for cosmetic, drug, medical device and other products, was arrested on charges of wire fraud and conspiracy following an indictment in New York federal court. The firm that bills itself as “the premier sunscreen testing laboratory” falsified results for 30 years by testing products on fewer subjects than it reported, federal prosecutors allege. Letzia pleaded not guilty but four AMA Labs employees pleaded guilty to similar charges in May. Get the whole story, and what this could mean for the approval or compliance status of products tested by AMA that are currently available.

Sunscreen Test Lab Used Fewer Subjects Than Reported, US Prosecutors Allege

L’Oréal E-Commerce Growth Approaches 50%: ‘We Are Now Clearly A Digital-First Company’

Reckitt Invests In AI Symptom Checker To ‘Unlock Self-Care’

CBD Suits Challenge ‘THC-Free’ Claims After Users Fail Drug Tests; Plaintiffs Bar May Just Be Warming Up

GSK And Pfizer Assemble Consumer Healthcare Leadership Team As JV Closes

Novartis CEO Explains Delay In Telling US FDA About Zolgensma Data Fraud: We Wanted To Understand It First

New Age Thinking: US FDA’s Temple Sees Third Era Of Drug Development

US FDA’s Rush Following Novartis’ Delay Suggests Strong Displeasure With Handling Of Zolgensma Data Manipulation

FDA’s Withdrawn Reg On Data Fraud Hangs Over Zolgensma Incident

Novartis’ Zolgensma Had Manipulated Data In Application, US FDA Says

Cannabis Industry Taking Legal Action Against EU Regulators Over CBD Novel Food Classification

FDA Determined To Update Cosmetics Regs After Claire’s Refuses To Recall Asbestos-Tainted Makeup

OTC Marketing Awards 2019 Winners Announced – GSK Crowned Company Of The Year, Pfizer’s Viagra Takes Best Brand

Reckitt Shaking Up Brain Health Market With Neuriva Dietary Supplement And Mobile App Launch In US

Novartis Pharma CEO Sees Zolgensma Supplanting Spinraza

BioMarin Is Carrying The Biggest Target On Its Back, Morningstar Says

Mortality Signal For Pfizer’s Xeljanz In Rheumatoid Arthritis Puts A Damper On JAK Class

Sanofi Prioritizes Cancer And Rare Diseases In Pipeline Shake-Up

What GSK’s Immunology Chief Did Next

Virtual AI Nurses And The Future Of Chronic Disease Management

Innovations In Market Access: The Will, But Not The Way?

Breakthrough Designation Rescissions: Who Might US FDA Drop Next?

Missed Opportunities: 10 Questions We Wish Senators Had Asked At The Drug Pricing Hearing

Goodbye To All That: EMA Leaves London After 24 years

Novartis Can’t Halt Janssen’s Promo Comparing Their Psoriasis Drugs

Gottlieb’s Short Tenure Will Be Felt Long After He Leaves US FDA

AbbVie’s Skyrizi Poised To Enter Packed Psoriasis Market

Six Questions For McKinsey Executives On Pharma’s Digital Experience

Gene Therapy Investment At All Time High, Commercialization Challenges Noted

Going Generic: Big Brands Poised To Lose Marketing Exclusivity In The US In 2019

Patient-Specific Drive Takes Ortho Group Corin Into TKR Robotics With Omni Purchase

EMA Issues Guidance On Medical Devices That Are Integral To Pharma Products

Scott Gottlieb Calls It Quits After An Active Tenure At US FDA

Eudamed – A Moving Target But On Track For March 2020 Partial Go-Live

Verseon Playing The Long Game To Level Up Drug Discovery

Deals Shaping The Medical Industry, February 2019

Into 2019: Risk, Uncertainty And A Return To Product Focus

From Device Centric To Disease Management: Ascensia Commits To Deeper Role In Diabetes

Cancer’s New Patient Demographic; Will Survivorship Change The Face Of Cancer Care?

Herbalife Shakes Up Executive Suite Due To CEO’s Earlier Statements On Expenses

Burt’s Bees Hopes Third Time’s A Charm For Toothpaste, This One With P&G

J&J CEO Sees Victory Ahead On Talc, Growth From Johnson’s Relaunch

Going ‘Beyond The Pill’ – Sanofi To Partner With Digital Health Start-ups In Europe

Germany Begins The Year With Two Possible Rx-To-OTC Switches

Top 10 Most Read Stories Of 2018